MedTrace Logo

Tinostamustine and Nivolumab in Advanced Melanoma

NCT03903458 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-04-08

No results posted yet for this study

Summary

This trial is a first-in-human drug combination with the first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule Tinostamustine (EDO-S101) and the anti-PD-1 monoclonal antibody Nivolumab in patients with refractory, locally advanced or metastatic melanoma.

Conditions

  • Malignant Melanoma

Interventions

DRUG

Tinostamustine

First-in-human administration of the combination of Tinostamustine and Nivolumab.

Sponsors & Collaborators

  • Markus Joerger

    lead OTHER

Principal Investigators

  • Markus Joerger, Prof. · Cantonal Hospital St. Gallen, Switzerland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-07
Primary Completion
2021-12-15
Completion
2024-03-15

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03903458 on ClinicalTrials.gov